BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Li B, Zhang C, Zhan YT. Nonalcoholic Fatty Liver Disease Cirrhosis: A Review of Its Epidemiology, Risk Factors, Clinical Presentation, Diagnosis, Management, and Prognosis. Can J Gastroenterol Hepatol 2018;2018:2784537. [PMID: 30065915 DOI: 10.1155/2018/2784537] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
Number Citing Articles
1 Toda-Oti KS, Stefano JT, Cavaleiro AM, Carrilho FJ, Correa-Gianella ML, Oliveira CPMS. Association of UCP3 Polymorphisms with Nonalcoholic Steatohepatitis and Metabolic Syndrome in Nonalcoholic Fatty Liver Disease Brazilian Patients. Metab Syndr Relat Disord 2022. [PMID: 35020496 DOI: 10.1089/met.2020.0104] [Reference Citation Analysis]
2 Altamirano J, Qi Q, Choudhry S, Abdallah M, Singal AK, Humar A, Bataller R, Borhani AA, Duarte-Rojo A. Non-invasive diagnosis: non-alcoholic fatty liver disease and alcoholic liver disease. Transl Gastroenterol Hepatol. 2020;5:31. [PMID: 32258535 DOI: 10.21037/tgh.2019.11.14] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
3 Koo DJ, Lee MY, Jung I, Moon SJ, Kwon H, Park SE, Rhee EJ, Lee WY. Changes in Insulin Resistance Index and the Risk of Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease without Diabetes: Kangbuk Samsung Health Study. Endocrinol Metab (Seoul) 2021;36:1016-28. [PMID: 34674510 DOI: 10.3803/EnM.2021.1110] [Reference Citation Analysis]
4 Hashemian M, Merat S, Poustchi H, Jafari E, Radmard AR, Kamangar F, Freedman N, Hekmatdoost A, Sheikh M, Boffetta P, Sinha R, Dawsey SM, Abnet CC, Malekzadeh R, Etemadi A. Red Meat Consumption and Risk of Nonalcoholic Fatty Liver Disease in a Population With Low Meat Consumption: The Golestan Cohort Study. Am J Gastroenterol 2021;116:1667-75. [PMID: 33767101 DOI: 10.14309/ajg.0000000000001229] [Reference Citation Analysis]
5 Scheinberg AR, John BV. MAFLD Versus NAFLD: Which Better Predicts the Risk of Atherosclerotic Cardiovascular Disease? Dig Dis Sci 2022. [PMID: 35579800 DOI: 10.1007/s10620-022-07512-w] [Reference Citation Analysis]
6 Mauri E, Gori M, Giannitelli SM, Zancla A, Mozetic P, Abbruzzese F, Merendino N, Gigli G, Rossi F, Trombetta M, Rainer A. Nano-encapsulation of hydroxytyrosol into formulated nanogels improves therapeutic effects against hepatic steatosis: An in vitro study. Mater Sci Eng C Mater Biol Appl 2021;124:112080. [PMID: 33947572 DOI: 10.1016/j.msec.2021.112080] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Choi EY, Choi JO, Park CY, Kim SH, Kim D. Water Extract of Artemisia annua L. Exhibits Hepatoprotective Effects Through Improvement of Lipid Accumulation and Oxidative Stress-Induced Cytotoxicity. J Med Food 2020;23:1312-22. [PMID: 33202166 DOI: 10.1089/jmf.2020.4696] [Reference Citation Analysis]
8 Kim YK, Kwon OS, Her KH. The grade of nonalcoholic fatty liver disease is an independent risk factor for gallstone disease: An observational Study. Medicine (Baltimore) 2019;98:e16018. [PMID: 31277096 DOI: 10.1097/MD.0000000000016018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
9 Pastore M, Grimaudo S, Pipitone RM, Lori G, Raggi C, Petta S, Marra F. Role of Myeloid-Epithelial-Reproductive Tyrosine Kinase and Macrophage Polarization in the Progression of Atherosclerotic Lesions Associated With Nonalcoholic Fatty Liver Disease. Front Pharmacol 2019;10:604. [PMID: 31191323 DOI: 10.3389/fphar.2019.00604] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
10 Xie C, Zhang Z, Yang M, Cao C, Zhou Y, Zhu Z, Gong W, Xu C, Yan L, Hu Z, Ai L, Peng Y. Lactiplantibacillus plantarum AR113 Exhibit Accelerated Liver Regeneration by Regulating Gut Microbiota and Plasma Glycerophospholipid. Front Microbiol 2022;12:800470. [DOI: 10.3389/fmicb.2021.800470] [Reference Citation Analysis]
11 Costello E, Rock S, Stratakis N, Eckel SP, Walker DI, Valvi D, Cserbik D, Jenkins T, Xanthakos SA, Kohli R, Sisley S, Vasiliou V, La Merrill MA, Rosen H, Conti DV, McConnell R, Chatzi L. Exposure to per- and Polyfluoroalkyl Substances and Markers of Liver Injury: A Systematic Review and Meta-Analysis. Environ Health Perspect 2022;130:46001. [PMID: 35475652 DOI: 10.1289/EHP10092] [Reference Citation Analysis]
12 Joseph J. Serum Marker Panels for Predicting Liver Fibrosis - An Update. Clin Biochem Rev 2020;41:67-73. [PMID: 32518428 DOI: 10.33176/AACB-20-00002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Polyzos SA, Kountouras J, Anastasilakis AD, Makras P, Hawa G, Sonnleitner L, Missbichler A, Doulberis M, Katsinelos P, Terpos E. Noggin levels in nonalcoholic fatty liver disease: the effect of vitamin E treatment. Hormones 2018;17:573-9. [DOI: 10.1007/s42000-018-0083-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
14 Nisly SA, Mihm AE, Gillette C, Davis KA, Tillett J. Safety of direct oral anticoagulants in patients with mild to moderate cirrhosis: a systematic review and meta-analysis. J Thromb Thrombolysis 2021. [PMID: 33728575 DOI: 10.1007/s11239-021-02424-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Guagnano MT, D'ardes D, Ilaria R, Santilli F, Schiavone C, Bucci M, Cipollone F. Non-Alcoholic Fatty Liver Disease and Metabolic Syndrome in Women: Effects of Lifestyle Modifications. JCM 2022;11:2759. [DOI: 10.3390/jcm11102759] [Reference Citation Analysis]
16 Liu B, Li Y, Li Y, Liu Y, Yan Y, Luo A, Ren H, She Q. Association of epicardial adipose tissue with non-alcoholic fatty liver disease: a meta-analysis. Hepatol Int 2019;13:757-65. [PMID: 31432447 DOI: 10.1007/s12072-019-09972-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
17 Prasun P, Ginevic I, Oishi K. Mitochondrial dysfunction in nonalcoholic fatty liver disease and alcohol related liver disease. Transl Gastroenterol Hepatol 2021;6:4. [PMID: 33437892 DOI: 10.21037/tgh-20-125] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
18 Ahmed NR, Kulkarni VV, Pokhrel S, Akram H, Abdelgadir A, Chatterjee A, Khan S. Comparing the Efficacy and Safety of Obeticholic Acid and Semaglutide in Patients With Non-Alcoholic Fatty Liver Disease: A Systematic Review. Cureus. [DOI: 10.7759/cureus.24829] [Reference Citation Analysis]
19 Roesch-dietlen F, González-santes M, Sánchez-maza Y, Díaz-roesch F, Cano-contreras A, Amieva-balmori M, García-zermeño K, Salgado-vergara L, Remes-troche J, Ortigoza-gutiérrez S. Influence of socioeconomic and cultural factors in the etiology of cirrhosis of the liver. Revista de Gastroenterología de México (English Edition) 2021;86:28-35. [DOI: 10.1016/j.rgmxen.2020.01.004] [Reference Citation Analysis]
20 Vecerzan L, Olteanu A, Maniu I, Boicean A, Cipăian CR, Dura H, Fleacă SR, Mihăilă RG. Thrombin Generation in Chronic Liver Diseases-A Pilot Study. Healthcare (Basel) 2021;9:550. [PMID: 34066706 DOI: 10.3390/healthcare9050550] [Reference Citation Analysis]
21 Fite RO, Kooti W, Azeze GA, Tesfaye B, Hagisso SN. Seroprevalence and factors associated with hepatitis B virus infection in blood donors in Ethiopia: a systematic review and meta-analysis. Arch Virol 2020;165:1039-48. [PMID: 32219546 DOI: 10.1007/s00705-020-04591-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
22 Kwon OS, Kim YK, Her KH, Kim HJ, Lee SD. Physical activity can reduce the prevalence of gallstone disease among males: An observational study. Medicine (Baltimore) 2020;99:e20763. [PMID: 32590752 DOI: 10.1097/MD.0000000000020763] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
23 Roesch-Dietlen F, González-Santes M, Sánchez-Maza YJ, Díaz-Roesch F, Cano-Contreras AD, Amieva-Balmori M, García-Zermeño KR, Salgado-Vergara L, Remes-Troche JM, Ortigoza-Gutiérrez S. Influence of socioeconomic and cultural factors in the etiology of cirrhosis of the liver. Rev Gastroenterol Mex (Engl Ed) 2021;86:28-35. [PMID: 32345507 DOI: 10.1016/j.rgmx.2020.01.002] [Reference Citation Analysis]
24 Colgan TJ, Zhao R, Roberts NT, Hernando D, Reeder SB. Limits of Fat Quantification in the Presence of Iron Overload. J Magn Reson Imaging 2021;54:1166-74. [PMID: 33783066 DOI: 10.1002/jmri.27611] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Fraiberg M, Elazar Z. Genetic defects of autophagy linked to disease. Prog Mol Biol Transl Sci 2020;172:293-323. [PMID: 32620246 DOI: 10.1016/bs.pmbts.2020.04.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
26 Enderes J, Teschke J, Manekeller S, Vilz TO, Kalff JC, Glowka TR. Chronic Liver Disease Increases Mortality Following Pancreatoduodenectomy. J Clin Med 2021;10:2521. [PMID: 34200183 DOI: 10.3390/jcm10112521] [Reference Citation Analysis]
27 Jamil M, Kichloo A, Soni RG, Jamal S, Khan MZ, Patel M, Albosta MS, Aljadah M, Bailey B, Singh J, Kanjwal K. Coexisting Cirrhosis Worsens Inpatient Outcomes in Patients With Infective Endocarditis: A Cross-Sectional Analysis of the National Inpatient Sample 2013-2014. Cureus 2020;12:e11826. [PMID: 33409068 DOI: 10.7759/cureus.11826] [Reference Citation Analysis]
28 Shabalala SC, Dludla PV, Mabasa L, Kappo AP, Basson AK, Pheiffer C, Johnson R. The effect of adiponectin in the pathogenesis of non-alcoholic fatty liver disease (NAFLD) and the potential role of polyphenols in the modulation of adiponectin signaling. Biomed Pharmacother 2020;131:110785. [PMID: 33152943 DOI: 10.1016/j.biopha.2020.110785] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
29 Le TNH, Choi HJ, Jun HS. Ethanol Extract of Liriope platyphylla Root Attenuates Non-Alcoholic Fatty Liver Disease in High-Fat Diet-Induced Obese Mice via Regulation of Lipogenesis and Lipid Uptake. Nutrients 2021;13:3338. [PMID: 34684339 DOI: 10.3390/nu13103338] [Reference Citation Analysis]
30 Dangl M, Eisenberg T, Grant JK, Vincent L, Colombo R, Sancassani R, Braghiroli J, Martin P, Vianna R, Nicolau-raducu R, Mendoza C. A comprehensive review of coronary artery disease in patients with end-stage liver disease. Transplantation Reviews 2022. [DOI: 10.1016/j.trre.2022.100709] [Reference Citation Analysis]
31 Praharaj DL, Mallick B, Nath P, Gupta S, Anand AC. Knowledge, attitude and practice of Gastroenterologists and hepatologists regarding vaccination in patients with chronic liver disease. Journal of Clinical and Experimental Hepatology 2022. [DOI: 10.1016/j.jceh.2022.03.010] [Reference Citation Analysis]
32 Chung GE, Chang Y, Cho Y, Cho EJ, Yoo JJ, Park SH, Han K, Shin DW, Yu SJ, Kim YJ, Yoon JH. The Change in Metabolic Syndrome Status and the Risk of Nonviral Liver Cirrhosis. Biomedicines 2021;9:1948. [PMID: 34944764 DOI: 10.3390/biomedicines9121948] [Reference Citation Analysis]
33 Oligschlaeger Y, Shiri-Sverdlov R. NAFLD Preclinical Models: More than a Handful, Less of a Concern? Biomedicines 2020;8:E28. [PMID: 32046285 DOI: 10.3390/biomedicines8020028] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
34 Johnson ND, Wu X, Still CD, Chu X, Petrick AT, Gerhard GS, Conneely KN, DiStefano JK. Differential DNA methylation and changing cell-type proportions as fibrotic stage progresses in NAFLD. Clin Epigenetics 2021;13:152. [PMID: 34353365 DOI: 10.1186/s13148-021-01129-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Jiang S, Xiao H, Wu Z, Yang Z, Ding B, Jin Z, Yang Y. NLRP3 sparks the Greek fire in the war against lipid-related diseases. Obes Rev 2020;21:e13045. [PMID: 32390276 DOI: 10.1111/obr.13045] [Reference Citation Analysis]